On Thursday, Travere Therapeutics received an upgrade to its Relative Strength (RS) Rating, from 61 to 73.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks compares to the rest of the market.
Over 100 years of market history reveals that the best stocks tend to have an 80 or better RS Rating in the early stages of their moves. See if Travere Therapeutics can continue to show renewed price strength and hit that benchmark.
Travere Therapeutics is building a consolidation with a 22.07 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
The company reported 0% earnings growth last quarter. Revenue gains came in at 111%.
The company holds the No. 48 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
